Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

-MYH11, group B - AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1, AML with normal karyotype with or without gene mutations (FLT3, NPM1, CEBPa) regardless of the allele ratio, and also AML with cytogenetic

  • 0 views
  • 28 Apr, 2022
  • 1 location
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

Background Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells. Standard treatment for SSA is a combination of 3 drugs (Cyclosporine [CsA], Eltrombopag [EPAG], and horse anti-thymocyte globulin [h-ATG]). Researchers want to see if starting people at …

cyclosporine
reticulocyte count
horse anti-thymocyte globulin
immunosuppression
platelet count
  • 12 views
  • 26 Jul, 2022
  • 1 location
RCT Study to Validate niPGT-A Clinical Benefit. (niPGT-A_RCT)

Chromosomal aneuploidies are linked with spontaneous miscarriages and abnormal offspring in human pregnancies. In addition, some types of aneuploidy are reported to prevent implantation. Thus, there is a need to identify the embryos with highest implantation potential on in vitro fertilization (IVF) programs. Since embryo morphology and kinetics have a …

embryo culture
intracytoplasmic sperm injection
discomfort
in vitro fertilization
  • 974 views
  • 26 Feb, 2022
  • 4 locations
Embryo Selection by Noninvasive Preimplantation Genetic Test (ESNi-PGT)

The objective of this study is to explore whether non-invasive chromosome screening (NICS) can be used as an effective indicator for embryos selection besides morphology through a multicenter randomized controlled trial, by comparing the differences of live birth rate, pregnancy rate and miscarriage rate between the two groups of embryo …

embryo culture
miscarriage
gonadotrophin releasing hormone analogue
controlled ovarian hyperstimulation
Accepts healthy volunteers
  • 0 views
  • 22 Apr, 2022
  • 11 locations
Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma (SOSAM)

in the last years, the patients' prognostic is associated with cytogenetic abnormalities. Oncological supportive care provides patients with a global perspective, in addition to specific

  • 0 views
  • 13 May, 2022
  • 1 location
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children (SCCLG-M5)

This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin …

  • 0 views
  • 20 Apr, 2022
  • 7 locations
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

evaluate the clinical efficacy and safety of azacitidine combined with HAG regimen for patients with int/high -risk MDS and AML-MRC with less than 30% blasts compared with azacitidine

  • 7 views
  • 09 Feb, 2022
  • 1 location
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone …

  • 0 views
  • 12 May, 2022
  • 1 location
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)

blast cells
bone marrow procedure
IDH2
cell transplantation
blood transfusion
  • 4 views
  • 15 Feb, 2022
  • 2 locations
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

Background GATA2 deficiency is a disease caused by mutations in the GATA2 gene. It can cause different types of leukemia and other diseases. Researchers want to see if a stem cell transplant can be used to treat this condition. A stem cell transplant will give stem cells from a matching …

direct bilirubin
cyclophosphamide
hematologic disorder
busulfan
remission
  • 26 views
  • 25 Jul, 2022
  • 1 location